Exploring novel integrin-α9β1 biomarker in cancer diagnosis and therapy: recent progress and insights

Integrin-α9β1 is one of the most important diagnostic and therapeutic targets for cancer due to its important roles in regulating tumor growth by promoting cell-to-cell interaction through the extracellular matrix and by promoting cellular signaling pathways that ultimately regulate tumor growth. α9β1 is a transmembrane heterodimeric receptor that is often overexpressed and plays a key role in many oncogenic processes, including invasion, vasculogenesis (angiogenesis), cell proliferation, metastasis, and epithelial-to-mesenchymal transition (EMT). By binding to important ligands (e.g., tenascin-C, osteopontin, and fibronectin), α9β1 initiates intracellular signaling cascades through pathways (e.g., FAK/Src, MEK/ERK, and Rac1), resulting in the promotion of tumor growth and alteration of the tumor microenvironment. Integration of advanced biosensing and molecular imaging technologies with abnormal integrin-α9β1 expression has the potential to serve as diagnostic markers for early detection and prognostic evaluation in the clinic. Furthermore, development of targeted therapies directed against α9β1 (e.g., ligand-blocking agents, small interfering RNAs, and monoclonal antibodies) has been shown to be effective in preclinical models of cancer by preventing tumor invasion and metastasis. Integrin-based imaging probes and novel nanotechnology-based delivery systems are improving the sensitivity and specificity of cancer detection and treatment. However, there are still technological challenges associated with the complexity of integrin signaling networks and the redundancy of ligand interactions. On a broader scale, integrin-α9β1 is a distinct and clinically important biomarker that can improve precision oncology by combining diagnostic (theranostic) and therapeutic approaches. Such an application requires further translational and clinical research. This review will provide a comprehensive description of the structure and function of integrin-α9β1 biology, the role of integrin-α9β1 in tumor formation, and the increasing role of integrin-α9β1 as a biomarker for cancer diagnosis and treatment. This review will also highlight the latest advancements in biosensing and targeted therapy strategies, identify current research impediments and knowledge deficits, and outline future opportunities for integrin-α9β1-based strategies to transition to clinical practice. • The review emphasizes how Integrin-α9β1 promotes the development of cancer through several ligand-binding mechanisms. • The study addresses the role of Integrin-α9β1 as a new theranostic target for imaging-guided cancer treatment. • The article focuses on how Integrin-α9β1 can be detected as a cancer biomarker using electrochemical, optical, and label-free biosensors.

Authors

Institutions

Publication Details

Journal
Health Nanotechnology
Published
2026-11-12
DOI
https://doi.org/10.1186/s44301-026-00042-8
Primary Topic
Cell Adhesion Molecules Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploring novel integrin-α9β1 biomarker in cancer diagnosis and therapy: recent progress and insights

Humaira Farooqi, Kamla Rawat, Kamal, Saima, Anam Nizam et al.
Health Nanotechnology
Cell Adhesion Molecules Research
article

Exploring novel integrin-α9β1 biomarker in cancer diagnosis and therapy: recent progress and insights

Humaira Farooqi, Kamla Rawat, Kamal, Saima, Anam Nizam, Manal Naved, Aqusa Gilani, Sana Khan, Mohd Rahil Hasan
article en

Abstract

Integrin-α9β1 is one of the most important diagnostic and therapeutic targets for cancer due to its important roles in regulating tumor growth by promoting cell-to-cell interaction through the extracellular matrix and by promoting cellular signaling pathways that ultimately regulate tumor growth. α9β1 is a transmembrane heterodimeric receptor that is often overexpressed and plays a key role in many oncogenic processes, including invasion, vasculogenesis (angiogenesis), cell proliferation, metastasis, and epithelial-to-mesenchymal transition (EMT). By binding to important ligands (e.g., tenascin-C, osteopontin, and fibronectin), α9β1 initiates intracellular signaling cascades through pathways (e.g., FAK/Src, MEK/ERK, and Rac1), resulting in the promotion of tumor growth and alteration of the tumor microenvironment. Integration of advanced biosensing and molecular imaging technologies with abnormal integrin-α9β1 expression has the potential to serve as diagnostic markers for early detection and prognostic evaluation in the clinic. Furthermore, development of targeted therapies directed against α9β1 (e.g., ligand-blocking agents, small interfering RNAs, and monoclonal antibodies) has been shown to be effective in preclinical models of cancer by preventing tumor invasion and metastasis. Integrin-based imaging probes and novel nanotechnology-based delivery systems are improving the sensitivity and specificity of cancer detection and treatment. However, there are still technological challenges associated with the complexity of integrin signaling networks and the redundancy of ligand interactions. On a broader scale, integrin-α9β1 is a distinct and clinically important biomarker that can improve precision oncology by combining diagnostic (theranostic) and therapeutic approaches. Such an application requires further translational and clinical research. This review will provide a comprehensive description of the structure and function of integrin-α9β1 biology, the role of integrin-α9β1 in tumor formation, and the increasing role of integrin-α9β1 as a biomarker for cancer diagnosis and treatment. This review will also highlight the latest advancements in biosensing and targeted therapy strategies, identify current research impediments and knowledge deficits, and outline future opportunities for integrin-α9β1-based strategies to transition to clinical practice. • The review emphasizes how Integrin-α9β1 promotes the development of cancer through several ligand-binding mechanisms. • The study addresses the role of Integrin-α9β1 as a new theranostic target for imaging-guided cancer treatment. • The article focuses on how Integrin-α9β1 can be detected as a cancer biomarker using electrochemical, optical, and label-free biosensors.

Health NanotechnologyVol. 2(1)
Galgotias University (IN), Jamia Hamdard (IN)
Good health and well-being
Cell Adhesion Molecules Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon